Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Receivables (2016 - 2025)

Historic Receivables for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.

  • Dr Reddys Laboratories' Receivables changed N/A to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year change of. This contributed to the annual value of $1.1 billion for FY2025, which is 984.79% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its Receivables stood at $1.2 billion for Q4 2025.
  • Dr Reddys Laboratories' 5-year Receivables high stood at $1.2 billion for Q4 2025, and its period low was -$256.8 million during Q3 2021.
  • Its 5-year average for Receivables is $529.7 million, with a median of $831.8 million in 2021.
  • Its Receivables has fluctuated over the past 5 years, first plummeted by 128082.65% in 2021, then soared by 12555.1% in 2023.
  • Over the past 5 years, Dr Reddys Laboratories' Receivables (Quarter) stood at $834.3 million in 2021, then increased by 9.57% to $914.1 million in 2022, then tumbled by 96.44% to $32.5 million in 2023, then tumbled by 253.5% to -$49.9 million in 2024, then soared by 2421.03% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q4 2025, -$88.1 million for Q3 2025, and -$56.2 million during Q2 2025.